Combined pulmonary fibrosis and emphysema

Expert Review of Respiratory Medicine

Volumn 7, Issue 1, 2013, Pages 19-32

  Papiris, Spyros A ^a   Triantafillidou, Christina ^b   Manali, Effrosyni D ^c   Kolilekas, Likurgos ^a   Baou, Katerina ^b   Kagouridis, Konstantinos ^a   Bouros, Demosthenes ^d  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

acute lung injury; cigarette smoking; idiopathic fibrotic nonspecific interstitial pneumonia; idiopathic pulmonary fibrosis; lung cancer; lung volumes discrepancy to diffusion capacity; pulmonary emphysema; pulmonary hypertension; smoking related pulmonary disease

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYGEN; SURFACTANT PROTEIN C; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FIBROSING ALVEOLITIS; GENETIC PREDISPOSITION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LANGERHANS CELL HISTIOCYTOSIS; LONG TERM CARE; LUNG CANCER; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG TRANSPLANTATION; OVERALL SURVIVAL; OXYGEN THERAPY; PNEUMONIA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SMOKING; SMOKING CESSATION;

EID: 84873134891     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.80     Document Type: Review

References (102)

1. American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am. Rev. Respir. Dis. 85, 762-768 (1962).
2. Snider GL, Stone PJ, Lucey EC et al. Eglin-c, a polypeptide derived from the medicinal leech, prevents human neutrophil elastase-induced emphysema and bronchial secretory cell metaplasia in the hamster. Am. Rev. Respir. Dis. 132(6), 1155-1161 (1985). (Pubitemid 16156364)
3. Takahashi M, Fukuoka J, Nitta N et al. Imaging of pulmonary emphysema: a pictorial review. Int. J. Chron. Obstruct. Pulmon. Dis. 3(2), 193-204 (2008). (Pubitemid 352037880)
4. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur. Respir. J. 26(5), 948-968 (2005). (Pubitemid 41632054)
5. Raghu G, Collard HR, Egan JJ et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183(6), 788-824 (2011).
6. Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum. Pathol. 39(9), 1275-1294 (2008).
7. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174(7), 810-816 (2006). (Pubitemid 44511663)
8. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am. J. Surg. Pathol. 18(2), 136-147 (1994). (Pubitemid 24046413)
9. Lynch DA, Travis WD, Müller NL et al. Idiopathic interstitial pneumonias: CT features. Radiology 236(1), 10-21 (2005). (Pubitemid 40861695)
10. Daniil ZD, Gilchrist FC, Nicholson AG et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 160(3), 899-905 (1999). (Pubitemid 29442028)
11. Silva CI, Müller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 247(1), 251-259 (2008).
12. Auerbach O, Garfinkel L, Hammond EC. Relation of smoking and age to findings in lung parenchyma: a microscopic study. Chest 65(1), 29-35 (1974).
13. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 84(5), 365-369 (1990). (Pubitemid 20287410)
14. Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration. 60(6), 354-358 (1993). (Pubitemid 23348646)
15. Lim TK. Respiratory failure from combined emphysema and pulmonary fibrosis. Singapore Med. J. 34(2), 169-171 (1993).
16. Doherty MJ, Pearson MG, O'Grady EA, Pellegrini V, Calverley PM. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 52(11), 998-1002 (1997). (Pubitemid 27514497)
17. Marten K, Milne D, Antoniou KM et al. Non-specific interstitial pneumonia in cigarette smokers: a CT study. Eur. Radiol. 19(7), 1679-1685 (2009).
18. Balbi B, Cottin V, Singh S, De Wever W, Herth FJ, Robalo Cordeiro C. Smokingrelated lung diseases: a clinical perspective. Eur. Respir. J. 35(2), 231-233 (2010).
19. Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related interstitial lung diseases: a concise review. Eur. Respir. J. 17(1), 122-132 (2001). (Pubitemid 32605656)
20. Fraig M, Shreesha U, Savici D, Katzenstein AL. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am. J. Surg. Pathol. 26(5), 647-653 (2002). (Pubitemid 34438725)
21. Jankowich MD, Polsky M, Klein M, Rounds S. Heterogeneity in combined pulmonary fibrosis and emphysema. Respiration. 75(4), 411-417 (2008). (Pubitemid 351685432)
22. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N. Engl. J. Med. 346(7), 484-490 (2002). (Pubitemid 34441739)
23. Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N. Engl. J. Med. 342(26), 1969-1978 (2000). (Pubitemid 30419093)
24. Katzenstein AL. Smoking-related interstitial fibrosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP. Mod. Pathol. 25(Suppl. 1), S68-S78 (2012).
25. Cottin V, Nunes H, Brillet PY et al.; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 26(4), 586-593 (2005).
26. Mäkelä MO. Is fibromyalgia a distinct clinical entity? The epidemiologist's evidence. Baillieres. Best Pract. Res. Clin. Rheumatol. 13(3), 415-419 (1999). (Pubitemid 30052715)
27. Rogliani P, Mura M, Mattia P et al. HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. Respir. Med. 102(12), 1753-1761 (2008).
28. Brillet PY, Cottin V, Letoumelin P et al. Combined apical emphysema and basal fibrosis syndrome (emphysema/fibrosis syndrome): CT imaging features and pulmonary function tests. J. Radiol. 90(1), 43-51(2009).
29. Cottin V, Le Pavec J, Prévot G et al.; GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur. Respir. J. 35(1), 105-111 (2010).
30. Mejía M, Carrillo G, Rojas-Serrano J et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136(1), 10-15 (2009).
31. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129(3), 746-752 (2006).
32. Hamada K, Nagai S, Tanaka S et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathicpulmonary fibrosis. Chest 131(3), 650-656 (2007). (Pubitemid 46446853)
33. Oswald-Mammosser M, Weitzenblum E, Quoix E et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 107(5), 1193-1198 (1995).
34. Schmidt SL, Nambiar AM, Tayob N et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur. Respir. J. 38(1), 176-183 (2011).
35. Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15(2), 265-271 (2010).
36. Akagi T, Matsumoto T, Harada T et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir. Med. 103(8), 1209-1215 (2009).
37. Kishaba T, Shimaoka Y, Fukuyama H et al. A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. BMJ Open 2(3) (2012).
38. Lee CH, Kim HJ, Park CM et al. The impact of combined pulmonary fibrosis and emphysema on mortality. Int. J. Tuberc. Lung Dis. 15(8), 1111-1116 (2011).
39. Cottin V, Nunes H, Mouthon L et al.; Groupe d'Etudes et de Recherche sur les Maladies 'Orphelines' Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 63(1), 295-304 (2011).
40. Grubstein A, Bendayan D, Schactman I, Cohen M, Shitrit D, Kramer MR. Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir. Med. 99(8), 948-954 (2005). (Pubitemid 40796537)
41. Daniil Z, Koutsokera A, Gourgoulianis K. Combined pulmonary fibrosis and emphysema in patients exposed to agrochemical compounds. Eur. Respir. J. 27(2), 434 (2006). (Pubitemid 43180924)
42. Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir. Care 51(3), 257-265 (2006). (Pubitemid 46888402)
43. Aduen JF, Zisman DA, Mobin SI et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin. Proc. 82(1), 48-54 (2007). (Pubitemid 46043228)
44. Silva DR, Gazzana MB, Barreto SS, Knorst MM. Idiopathic pulmonary fibrosis and emphysema in smokers. J. Bras. Pneumol. 34(10), 779-786 (2008).
45. Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 188(5), 365-373 (2010).
46. Kurashima K, Takayanagi N, Tsuchiya N et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 15(5), 843-848 (2010).
47. Todd NW, Atamas SP. Survival in pulmonary fibrosis combined with emphysema: likely defined by characteristics of specific patient subpopulations. Fibrogenesis Tissue Repair 4, 17 (2011).
48. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 16(2), 326-331 (2011).
49. Tasaka S, Mizoguchi K, Funatsu Y et al. Cytokine profile of bronchoalveolar lavage fluid in patients with combined pulmonary fibrosis and emphysema. Respirology 17(5), 814-820 (2012).
50. Chiba S, Ohta H, Abe K et al. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm. Med. 2012, 492960 (2012).
51. Odani K, Murata Y, Yoshida S. Computed tomographic evaluation in the cases of coexistence of pulmonary emphysema with idiopathic pulmonary fibrosis. Danso Eizo kenkyukai Zasshi 31, 25-29 (2004).
52. Cottin V, Cordier JF, Wells AU. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival: a response. Fibrogenesis Tissue Repair 4, 16 (2011).
53. Ley B, Collard HR, King TE Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183(4), 431-440 (2011).
54. Papiris SA, Manali ED, Kolilekas L et al. IPF exacerbations: unravelling Ariadne's thread. Crit. Care 14(6), 246 (2010).
55. Newell JD Jr. CT of emphysema. Radiol. Clin. North Am. 40(1), 31-42, vii (2002).
56. Akira M, Inoue Y, Kitaichi M, Yamamoto S, Arai T, Toyokawa K. Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings. Radiology 251(1), 271-279 (2009).
57. Fell CD, Martinez FJ, Liu LX et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 181(8), 832-837 (2010).
58. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 141(1), 222-231 (2012).
59. Lederer DJ, Enright PL, Kawut SM et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am. J. Respir. Crit. Care Med. 180(5), 407-414 (2009).
60. Washko GR, Lynch DA, Matsuoka S et al. Identification of early interstitial lung disease in smokers from the COPD Gene Study. Acad. Radiol. 17(1), 48-53 (2010).
61. Washko GR, Hunninghake GM, Fernandez IE et al.; COPD Gene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N. Engl. J. Med. 364(10), 897-906 (2011).
62. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur. Respir. J. 30(5), 835-839 (2007). (Pubitemid 351194784)
63. du Bois R, King TE Jr. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax 62(11), 1008-1012 (2007).
64. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 155(1), 242-248 (1997). (Pubitemid 27053171)
65. Steele MP, Speer MC, Loyd JE et al. Clinical and pathologic features of familial interstitial pneumonia. Am. J. Respir. Crit. Care Med. 172(9), 1146-1152 (2005). (Pubitemid 43066651)
66. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc. Am. Thorac. Soc. 3(4), 293-298 (2006). (Pubitemid 43845405)
67. Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134(2), 136-151 (2001). (Pubitemid 32096342)
68. Yousem SA. Respiratory bronchiolitisassociated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. Mod. Pathol. 19(11), 1474-1479 (2006). (Pubitemid 44624167)
69. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 25(3), 552-563 (2005). (Pubitemid 40331188)
70. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 29(15), 4325-4339 (2009).
71. Coward WR, Watts K, Feghali-Bostwick CA, Jenkins G, Pang L. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 30(12), 2874-2886 (2010).
72. Hao LY, Armanios M, Strong MA et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123(6), 1121-1131 (2005). (Pubitemid 41785425)
73. Armanios MY, Chen JJ, Cogan JD et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356(13), 1317-1326 (2007). (Pubitemid 46513297)
74. Tsakiri KD, Cronkhite JT, Kuan PJ et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl Acad. Sci. USA 104(18), 7552-7557 (2007). (Pubitemid 47185944)
75. Cronkhite JT, Xing C, Raghu G et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178(7), 729-737 (2008).
76. Alder JK, Guo N, Kembou F et al. Telomere length is a determinant of emphysema susceptibility. Am. J. Respir. Crit. Care Med. 184(8), 904-912 (2011).
77. Diaz de Leon A, Cronkhite JT, Katzenstein AL et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 5(5), e10680 (2010).
78. Lundblad LK, Thompson-Figueroa J, Leclair T et al. Tumor necrosis factor-α overexpression in lung disease: a single cause behind a complex phenotype. Am. J. Respir. Crit. Care Med. 171(12), 1363-1370 (2005). (Pubitemid 40800508)
79. Hoyle GW, Li J, Finkelstein JB et al. Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am. J. Pathol. 154(6), 1763-1775 (1999). (Pubitemid 29262858)
80. Fulkerson PC, Fischetti CA, Hassman LM, Nikolaidis NM, Rothenberg ME. Persistent effects induced by IL-13 in the lung. Am. J. Respir. Cell Mol. Biol. 35(3), 337-346 (2006). (Pubitemid 44353402)
81. Gauldie J, Kolb M, Ask K, Martin G, Bonniaud P, Warburton D. Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc. Am. Thorac. Soc. 3(8), 696-702 (2006). (Pubitemid 44788227)
82. Bonniaud P, Kolb M, Galt T et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. J. Immunol. 173(3), 2099-2108 (2004). (Pubitemid 38971648)
83. Chen H, Sun J, Buckley S et al. Abnormal mouse lung alveolarization caused by Smad3 deficiency is a developmental antecedent of centrilobular emphysema. Am. J. Physiol. Lung Cell Mol. Physiol. 288(4), L683-L691 (2005). (Pubitemid 40404136)
84. Lucattelli M, Bartalesi B, Cavarra E et al. Is neutrophil elastase the missing link between emphysema and fibrosis? Evidence from two mouse models. Respir. Res. 6, 83 (2005).
85. Wert SE, Yoshida M, LeVine AM et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc. Natl Acad. Sci. USA 97(11), 5972-5977 (2000). (Pubitemid 30367508)
86. Fujita M, Mason RJ, Cool C, Shannon JM, Hara N, Fagan KA. Pulmonary hypertension in TNF-α-overexpressing mice is associated with decreased VEGF gene expression. J. Appl. Physiol. 93(6), 2162-2170 (2002). (Pubitemid 35379344)
87. Couillin I, Vasseur V, Charron S et al. IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. J. Immunol. 183(12), 8195-8202 (2009).
88. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1β causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am. J. Respir. Cell Mol. Biol. 32(4), 311-318 (2005). (Pubitemid 40478306)
89. Cottin V, Reix P, Khouatra C, Thivolet-Béjui F, Feldmann D, Cordier JF. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 66(10), 918-919 (2011).
90. van Moorsel CH, van Oosterhout MF, Barlo NP et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am. J. Respir. Crit. Care Med. 182(11), 1419-1425 (2010).
91. Cottin V, Cordier JF. SFTPC mutations in patients with familial pulmonary fibrosis: combined with emphysema? Am. J. Respir. Crit. Care Med. 183(8), 1113; author reply 1113-1113; author reply 1114 (2011).
92. Mechri M, Epaud R, Emond S et al. Surfactant protein C gene (SFTPC) mutation-associated lung disease: high-resolution computed tomography (HRCT) findings and its relation to histological analysis. Pediatr. Pulmonol. 45(10), 1021-1029 (2010).
93. Papiris SA, Kagouridis K, Kolilekas L, Triantafillidou C, Tsangaris I, Manali ED. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation? Eur. Respir. J. 40(3), 794-795 (2012).
94. Papiris SA, Kagouridis K, Bouros D. Serologic evaluation in idiopathic interstitial pneumonias. Curr. Opin. Pulm. Med. 18(5), 433-440 (2012).
95. Papiris SA, Manali ED, Kolilekas L, Triantafillidou C, Tsangaris I, Kagouridis K. Steroids in idiopathic pulmonary fibrosis acute exacerbation: defenders or killers? Am. J. Respir. Crit. Care Med. 185(5), 587-588 (2012).
96. Stolz D, Rasch H, Linka A et al. A randomised, controlled trial of bosentan in severe COPD. Eur. Respir. J. 32(3), 619-628 (2008).
97. Blanco I, Gimeno E, Munoz PA et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 181(3), 270-278 (2010).
98. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT); Galiè N, Hoeper MM. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 34(6), 1219-1263 (2009).
99. Kreider M, Kotloff RM. Selection for candidates for lung transplantation. Proc. Am. Thorac. Soc. 6(1), 20-27 (2009).
100. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality. American Lung Association, Epidemiology and Statistics Unit, Research and Program Services Division August 2011. www.lung.org/finding-cures/our- research/ trend-reports/copd-trend-report.pdf (Accessed 1 July 2012)
101. US Public Health Service. Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. US Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control. PHS Publication No. 1103, 1964. http://profiles.nlm.nih.gov/ps/access/ NNBBMQ.pdf (Accessed 1 July 2012)
102. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011).